US4282240A - Amino substituted tetrahydrobenzindoles - Google Patents
Amino substituted tetrahydrobenzindoles Download PDFInfo
- Publication number
- US4282240A US4282240A US06/096,948 US9694879A US4282240A US 4282240 A US4282240 A US 4282240A US 9694879 A US9694879 A US 9694879A US 4282240 A US4282240 A US 4282240A
- Authority
- US
- United States
- Prior art keywords
- alkyl
- composition
- compounds
- halogen
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention is concerned with certain aminosubstituted tetrahydrobenzindoles, their preparation and pharmaceutical use.
- the compounds have pharmacological activity, e.g. antihypertensive, prolactin inhibition, anti-Parkinson agent.
- An embodiment of the present invention is compounds of the formula ##STR4## and pharmaceutically acceptable salts thereof wherein R 1 is H, alkyl or aryl
- R 1 is H or halogen
- R 2 is H, alkyl or aralkyl
- R 3 is H, OH, halogen, OCH 3 or C 1 -C 3 alkyl.
- the positions on the I ring structure are numbered as indicated.
- alkyl includes straight and branched chain alkyls having up to 6 carbon atoms. Alkyl of 1 to 3 carbon atoms, e.g. methyl, isopropyl, ethyl and the like are preferred.
- aryl includes hydrocarbon aryl groups and especially those containing 6 carbon atoms in the aryl ring. Phenyl and monsubstituted phenyl groups wherein the substituents are halogen, C 1 -C 3 alkyl or C 1 -C 3 alkoxy are preferred aryl groups.
- aralkyl includes phenyl-and monosubstitutedphenyl-C 1 -C 3 -alkyl group.
- the preferred substituted phenyl group is the same as that defined by the term aryl above.
- Examples of aralkyl groups are benzyl, bromophenyl-C 3 H 6 --, ethoxyphenyl -C 2 H 4 , methylphenyl-CH 2 -- and the like.
- halogen includes Br, Cl, F and iodo with Br, Cl and F being preferred and Br and Cl being more preferred.
- the pharmaceutically acceptable salts are the salts of formula I with suitable inorganic or organic acids.
- suitable organic acids are carboxylic acids such as acetic acid, fumaric acid, maleic acid, succinic acid, pamoic acid, pivalic acid and oxalic acid and non carboxylic acid such as isethionic acid naphthalene disulfonic acid and the like.
- Useful inorganic acids are the hydrohalides such as HCl and HBr, H 2 SO 4 , phosphoric acid and the like.
- alkyl is C 1 -C 3 alkyl, preferably methyl and R 2 is H.
- Alkyl is CH 3 and R 1 , R 2 , and R 3 are all H.
- R 2 is H.
- aryl is phenyl and R 1 , R 2 and R 3 are all H.
- the compounds of the present invention are active antihypertensives.
- a representative compound was tested in a protocol using a spontaneously hypertensive (SH) rat model to demonstrate this activity. This test indicates that the present compounds would be useful in treating hypertension in hypertensive human patients.
- SH spontaneously hypertensive
- the compounds of the present invention are administered to the hypertensive patient by any convenient mode of administration e.g. orally or parenterally using appropriate dosage e.g. tablets, emulsions, solutions, capsules for oral administration and solutions, suspensions, emulsions for parenteral administration.
- appropriate dosage e.g. tablets, emulsions, solutions, capsules for oral administration and solutions, suspensions, emulsions for parenteral administration.
- Conventional procedures are used to prepare suitable pharmaceutical compositions in proper dosage forms using conventional, pharmaceutically acceptable diluents, compounding ingredients, and the like.
- Sufficient amount of a compound of the present invention is administered to the patient to produce the desired therapeutic effect i.e. lowering of high blood pressure.
- Suitable dosages will thus vary and the daily dosage in humans may range from about 10 mg. to about 3000 mg., preferably about 20 mg. to about 1000 mg. and more preferably about 50 mg. to about 500 mg.
- the present compounds also have other pharmacological properties which make them useful in humans as prolactin inhibitors or for treating Parkinson's disease, at appropriate dosages and using appropriate modes of administration e.g. parenterally or orally.
- the compounds of the present invention may be prepared by any available process.
- a convenient process useful for this preparation is illustrated by the following set of equations: the term tos stands for the tosylate or p-tolysulphonyl moiety. ##STR7##
- the compound A is known [see Bowman et al., J. C. S. Perkin I, 438 (1973)].
- Acylation of A with a suitable anhydride or acyl halide introduces the ##STR8## substituent on the amino N (compound B).
- the ketone group adjacent to the amino group is then thioketalized by treatment with 1,3-propanedithiol and trimethylsilylchloride in chloroform using conventional conditions to yield the C product.
- the thioketal group is removed by treatment with a suitable catalyst such as Raney nickel to yield compound D.
- the product (D) obtained is then hydrogenated using an appropriate system such as lithum aluminum hydride to yield the desired final product E.
- Step A 4-Acetamino-1,3,4,5-tetrahydro-1-(p-tolysulphonyl)benz[c,d]indol-5-one
- Step B 4-Acetamino-1,3,4,5-tetrahydro-1-(p-tolylsulphonyl)benz[c,d]indol-5-one(1,3-propylenedi-thio Ketal)
- Step C 4-Acetamino-1,3,4,5-tetrahydro-1-(p-tolylsulphonyl) benz[c,d]indole
- Step D 4-(N-Ethylamino)-1,3,4,5-tetrahydrobenz[c,d]indole
- this derivative may be prepared by treating the 4-N-protected indole with an appropriate alkylating reagent such as methyl iodide in basic medium to obtain the corresponding indole N substituted compound.
- the compound (ii) may be converted to the corresponding compound where the group in the 8-position is OH by suitably cleaving the OCH 3 group by using e.g. trimethylsilyl iodide [see J. Org. Chem. 42, 3761-3764 (1977)].
- Halogenation of the tetrahydrobenzindole moiety in the 2-position can be carried out using the process described in von F. Troxler in Helv. Clinc. Acta 40, 2160 (1957).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/096,948 US4282240A (en) | 1979-11-23 | 1979-11-23 | Amino substituted tetrahydrobenzindoles |
EP80107188A EP0029581B1 (en) | 1979-11-23 | 1980-11-19 | Amino substituted tetrahydrobenzindoles, a process for preparing and a pharmaceutical composition containing the same |
AT80107188T ATE9690T1 (de) | 1979-11-23 | 1980-11-19 | Amino-substituierte tetrahydrobenzindole, verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen. |
DE8080107188T DE3069381D1 (en) | 1979-11-23 | 1980-11-19 | Amino substituted tetrahydrobenzindoles, a process for preparing and a pharmaceutical composition containing the same |
GR63410A GR72131B (ja) | 1979-11-23 | 1980-11-20 | |
PT72088A PT72088B (en) | 1979-11-23 | 1980-11-21 | Process for preparing amino substituted tetrahydrobenzindoles |
DK497680A DK497680A (da) | 1979-11-23 | 1980-11-21 | Fremgangsmaade til fremstilling af tetrahydrobenzindoler |
ES497063A ES497063A0 (es) | 1979-11-23 | 1980-11-21 | Un procedimiento de preparacion de tetra hidrobenzoindoles. |
JP16476980A JPS5687562A (en) | 1979-11-23 | 1980-11-25 | Amino substituted tetrahydrobenzindole |
US06/240,350 US4501900A (en) | 1979-11-23 | 1981-03-04 | Amino substituted tetrahydrobenzindoles |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/096,948 US4282240A (en) | 1979-11-23 | 1979-11-23 | Amino substituted tetrahydrobenzindoles |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/240,350 Continuation US4501900A (en) | 1979-11-23 | 1981-03-04 | Amino substituted tetrahydrobenzindoles |
Publications (1)
Publication Number | Publication Date |
---|---|
US4282240A true US4282240A (en) | 1981-08-04 |
Family
ID=22259890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/096,948 Expired - Lifetime US4282240A (en) | 1979-11-23 | 1979-11-23 | Amino substituted tetrahydrobenzindoles |
Country Status (9)
Country | Link |
---|---|
US (1) | US4282240A (ja) |
EP (1) | EP0029581B1 (ja) |
JP (1) | JPS5687562A (ja) |
AT (1) | ATE9690T1 (ja) |
DE (1) | DE3069381D1 (ja) |
DK (1) | DK497680A (ja) |
ES (1) | ES497063A0 (ja) |
GR (1) | GR72131B (ja) |
PT (1) | PT72088B (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4576959A (en) * | 1984-02-06 | 1986-03-18 | Eli Lilly And Company | 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles |
AU572258B2 (en) * | 1984-02-06 | 1988-05-05 | Eli Lilly And Company | 6-substituted-4-dialkyl amino tetrahydro benz (c,d) indoles |
US4983622A (en) * | 1984-02-06 | 1991-01-08 | Eli Lilly And Company | 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles |
US5026869A (en) * | 1984-02-06 | 1991-06-25 | Eli Lilly And Company | 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles |
US5229409A (en) * | 1990-08-15 | 1993-07-20 | Eli Lilly And Company | 6-substituted-tetrahydrobenz[cd]indoles |
US5244912A (en) * | 1991-03-28 | 1993-09-14 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof |
US5302612A (en) * | 1990-02-26 | 1994-04-12 | Eli Lilly And Company | 6-substituted-hexahydrobenz[cd]indoles |
US5364856A (en) * | 1991-03-28 | 1994-11-15 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU560459B2 (en) * | 1982-06-01 | 1987-04-09 | Abbott Laboratories | Tetrahydro-benzo(e) isoindolines |
DE3346573A1 (de) * | 1983-12-23 | 1985-07-04 | Troponwerke GmbH & Co KG, 5000 Köln | 1,3,4,5-tetrahydrobenz(c,d)indole, ein verfahren zu ihrer herstellung und ihre verwendung |
CA1266482A1 (en) * | 1984-05-24 | 1990-03-06 | Carl Kaiser | 6-oxygenated-1,3,4,5-tetrahydrobenz(cd)indol-4-amines |
DE3809155A1 (de) * | 1988-03-18 | 1989-09-28 | Bayer Ag | 1,3,4,5-tetrahydrobenz-(c,d)-indole |
US5204340A (en) * | 1989-04-11 | 1993-04-20 | Eli Lilly And Company | Tetrahydrobenz(c,d)indole serotonin agonists |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3200130A (en) * | 1963-08-27 | 1965-08-10 | Upjohn Co | Derivatives of 1, 3, 4, 5-tetrahydro-benz[cd]indoles |
US4110339A (en) * | 1977-11-25 | 1978-08-29 | Eli Lilly And Company | 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole |
-
1979
- 1979-11-23 US US06/096,948 patent/US4282240A/en not_active Expired - Lifetime
-
1980
- 1980-11-19 AT AT80107188T patent/ATE9690T1/de not_active IP Right Cessation
- 1980-11-19 EP EP80107188A patent/EP0029581B1/en not_active Expired
- 1980-11-19 DE DE8080107188T patent/DE3069381D1/de not_active Expired
- 1980-11-20 GR GR63410A patent/GR72131B/el unknown
- 1980-11-21 ES ES497063A patent/ES497063A0/es active Granted
- 1980-11-21 DK DK497680A patent/DK497680A/da not_active Application Discontinuation
- 1980-11-21 PT PT72088A patent/PT72088B/pt unknown
- 1980-11-25 JP JP16476980A patent/JPS5687562A/ja active Granted
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3200130A (en) * | 1963-08-27 | 1965-08-10 | Upjohn Co | Derivatives of 1, 3, 4, 5-tetrahydro-benz[cd]indoles |
US4110339A (en) * | 1977-11-25 | 1978-08-29 | Eli Lilly And Company | 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole |
Non-Patent Citations (5)
Title |
---|
Bach et al.; J. Med. Chem., vol. 17; pp. 312-313 (1974). * |
Bowman et al., J.C.S. Perk. I. pp. 438-442 (1973). * |
Harris et al., Chem. Abs., vol. 54:12367f (1960) * |
Stoll et al., Chem. Abs., vol. 46:1539f-1540d (1959). * |
Stoll et al., Chem. Abs., vol. 47:2167d (1953). * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU572258B2 (en) * | 1984-02-06 | 1988-05-05 | Eli Lilly And Company | 6-substituted-4-dialkyl amino tetrahydro benz (c,d) indoles |
US4983622A (en) * | 1984-02-06 | 1991-01-08 | Eli Lilly And Company | 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles |
US5026869A (en) * | 1984-02-06 | 1991-06-25 | Eli Lilly And Company | 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles |
US4576959A (en) * | 1984-02-06 | 1986-03-18 | Eli Lilly And Company | 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles |
US5302612A (en) * | 1990-02-26 | 1994-04-12 | Eli Lilly And Company | 6-substituted-hexahydrobenz[cd]indoles |
US5470853A (en) * | 1990-02-26 | 1995-11-28 | Eli Lilly And Company | 6-substituted-hexahydrobenz [CD] indoles |
US5229409A (en) * | 1990-08-15 | 1993-07-20 | Eli Lilly And Company | 6-substituted-tetrahydrobenz[cd]indoles |
US5364856A (en) * | 1991-03-28 | 1994-11-15 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles |
US5244912A (en) * | 1991-03-28 | 1993-09-14 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof |
US5594019A (en) * | 1991-03-28 | 1997-01-14 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles |
US5624944A (en) * | 1991-03-28 | 1997-04-29 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[cd]indoles |
US5641797A (en) * | 1991-03-28 | 1997-06-24 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[cd] indoles |
US5643930A (en) * | 1991-03-28 | 1997-07-01 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5,-tetrahydrobenz [cd]indoles |
US5665743A (en) * | 1991-03-28 | 1997-09-09 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD] indoles |
US5665758A (en) * | 1991-03-28 | 1997-09-09 | Eli Lilly And Company | 6-Heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD] indoles |
US5674884A (en) * | 1991-03-28 | 1997-10-07 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz cd! indoles |
US5736562A (en) * | 1991-03-28 | 1998-04-07 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz CD ! indoles |
Also Published As
Publication number | Publication date |
---|---|
GR72131B (ja) | 1983-09-19 |
JPH0139425B2 (ja) | 1989-08-21 |
DE3069381D1 (en) | 1984-11-08 |
EP0029581B1 (en) | 1984-10-03 |
PT72088A (en) | 1980-12-01 |
ES8203343A1 (es) | 1982-04-01 |
EP0029581A2 (en) | 1981-06-03 |
ES497063A0 (es) | 1982-04-01 |
JPS5687562A (en) | 1981-07-16 |
PT72088B (en) | 1982-09-01 |
EP0029581A3 (en) | 1981-09-02 |
DK497680A (da) | 1981-05-24 |
ATE9690T1 (de) | 1984-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100343060B1 (ko) | 벤조푸릴유도체,이의제조방법및이를함유하는약제 | |
US4282240A (en) | Amino substituted tetrahydrobenzindoles | |
US4503066A (en) | Spiro-linked pyrrolidine-2,5-diones active as enzyme aldose reductase inhibitors | |
JPH0643393B2 (ja) | インドリノン誘導体 | |
US4374841A (en) | Pyridoxine derivatives, and use in therapeutics | |
US5164404A (en) | Hydrazone derivatives and their use | |
US4013668A (en) | 5-(1,1-diphenyl-3-(5- or 6-hydroxy-2-azabicyclo(2.2.2)oct-2-yl)propyl)-2-alkyl-1,3,4-oxadiazoles and related compounds | |
US4690924A (en) | 1,7-Naphthyridine derivatives and medicinal preparations containing same | |
US4238486A (en) | Indolobenzoxazines | |
HU202863B (en) | Process for producing flavon derivatives | |
GB1568398A (en) | Triazolo pyridazine derivatives | |
US4501900A (en) | Amino substituted tetrahydrobenzindoles | |
JPS60185780A (ja) | テトラヒドロピリドインドール神経弛緩剤 | |
US3970757A (en) | Tetrahydro-carbazole derivatives as gastric anti-secretory agents | |
US5021445A (en) | Compounds useful for the treatment of hypoglycemia | |
US4861778A (en) | 2,3-dihydrophthalazine-1,4-diones | |
JPH0536436B2 (ja) | ||
JP2726999B2 (ja) | イミダゾ[2,1−b]ベンゾチアゾール誘導体及び該化合物を有効成分とする抗潰瘍剤 | |
US5064852A (en) | Indolinone derivatives | |
US5310750A (en) | Heterocyclic compounds useful as α2 -adrenoceptor antagonists | |
US4235903A (en) | 1-Hydroxyalkanamine tetrahydrocarbazoles and cyclopent[b]indoles, compositions and method of use | |
US4777181A (en) | Alpha-2-antagonistic substituted 4-fluoro-isoindolines | |
US4960785A (en) | Indolinone derivatives | |
SE453293B (sv) | 3,3-dialkyl- och 3,3-alkylen-indolinderivat, sett att framstella dessa och farmaceutiska kompositioner innehallande desamma | |
US4319029A (en) | Hydroxyalkanamide tetrahydrocarbazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MERCK & CO.INC. LINCOLN AVE. RAHWAY, N.J. A CORP.O Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:BALDWIN JOHN J.;JONES JAMES H.;LUNDELL GEORGE F.;REEL/FRAME:003829/0537 Effective date: 19791119 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |